Literature DB >> 8749906

Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders.

R M Bashir1, J H Lewis.   

Abstract

Hepatic injury from agents in this category is rare. For example, only a handful of cases of H2-receptor antagonist-related liver injury have been reported despite the hundreds of millions of doses prescribed since the introduction of these drugs more than 15 years ago. Hepatotoxicity from sulfasalazine is uncommon but may be fatal. Injury from other agents used to treat inflammatory bowel disease also may be seen, including veno-occlusive disease from azathioprine. Of increasing importance is the toxicity from alternative health supplements, such as herbal remedies, that may cause acute, sometimes fatal, hepatic necrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749906

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  5 in total

Review 1.  Preventive care in chronic liver disease.

Authors:  T R Riley; J P Smith
Journal:  J Gen Intern Med       Date:  1999-11       Impact factor: 5.128

2.  A case of supplement-induced hepatotoxicity.

Authors:  Fong-Kuei Frank Cheng; Peter Dunaway
Journal:  Case Rep Med       Date:  2010-08-15

Review 3.  Unraveling the Molecular Mechanism of Traditional Chinese Medicine: Formulas Against Acute Airway Viral Infections as Examples.

Authors:  Yi Shin Eng; Chien Hsing Lee; Wei Chang Lee; Ching Chun Huang; Jung San Chang
Journal:  Molecules       Date:  2019-09-27       Impact factor: 4.411

4.  Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.

Authors:  Adnan Malik; Ani A Kardashian; Kais Zakharia; Christopher L Bowlus; James H Tabibian
Journal:  Liver Res       Date:  2019-05-27

Review 5.  Liver manifestations and complications in inflammatory bowel disease: A review.

Authors:  Rui Gaspar; Catarina Castelo Branco; Guilherme Macedo
Journal:  World J Hepatol       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.